Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor

Published:2016-04-06 Issue:5 Volume:18 Page:454-462
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

DeFronzo R. A.¹,Chilton R.²,Norton L.¹,Clarke G.³,Ryder R. E. J.⁴,Abdul-Ghani M.¹

Affiliation:

1. Diabetes Division; University of Texas Health Science Center and Texas Diabetes Institute; San Antonio TX USA

2. Cardiology Division; University of Texas Health Science Center and Texas Diabetes Institute; San Antonio TX USA

3. Diabetes Division and Department of Radiology; University of Texas Health Science Center and Texas Diabetes Institute; San Antonio TX USA

4. Diabetes and Endocrine Unit; City Hospital; Birmingham UK

Funder

South Texas Veterans Administration Health Care System

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12652/fullpdf

Reference75 articles.

1. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015

2. Assessment and management of acute coronary syndromes (ACS): a Canadian perspective on current guideline-recommended treatment-part 2: ST-segment elevation myocardial infarction;Fitchett;Can J Cardiol,2011

3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33);Group UPDSU;Lancet,1998

4. 10-year follow-up of intensive glucose control in type 2 diabetes;Holman;N Engl J Med,2008

5. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial;Ridker;Lancet,2009

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A multicentre, double‐blind, placebo‐controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add‐on therapy in type 2 diabetic patients treated with metformin and dapagliflozin;Diabetes, Obesity and Metabolism;2024-02-29

2. NAFLD and type 2 diabetes: A practical guide for the joint management;Gastroenterología y Hepatología (English Edition);2023-12

3. Perfecting the Puzzle of Pathophysiology: Exploring Combination Therapy in the Treatment of Type 2 Diabetes;Diabetology;2023-09-07

4. A pioglitazon újrafelfedezése;Orvosi Hetilap;2023-07-02

5. Clinical pharmacology of antidiabetic drugs: What can be expected of their use?;La Presse Médicale;2023-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3